anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A method of making Cu-Ag3PO4 nanoparticles is provided. The method includes forming a mixture of at least one silver salt, at least one phosphate salt, and at least one copper (II) salt. The method further includes dissolving the mixture in water. The method further includes sonicating the mixture. The method further includes precipitating the Cu-Ag3PO4 nanoparticles or “nanoparticles”. The copper is present in the nanoparticles in an amount of 2 to 23 weight percent (wt.%) based on the total weight of the Cu-Ag3PO4. The nanoparticles of the present disclosure find application in treating cervical cancer, and colorectal cancer. The nanoparticles may also be used in photodegrading environmental pollutants.
Single arm: subjects with tumor types with high expression of PVRL2 will receive study treatment with COM701 in combination with BMS-986207 and nivolumab. All study drugs will be administered IV every 4 weeks.
1,177,094. U.V. stabilized cosmetics. CIBA Ltd. 7 Feb., 1967 [7 Feb., 1966], No. 5725/67. Heading A5B. [Also in Divisions C2, C3, C4, CS and C6] The invention comprises a composition of matter consisting of an organic material that can be damaged by ultraviolet rays having incorporated therein a compound of the formula where A and B are different benzene or naphthalene residue free from hydroxyl groups in ortho-positions to the amide groups and which may contain further substituents that contain no more than 20 carbon atoms and do not displace the adsorption maximum of the compound towards values above 400 mÁ. The organic material may be a cosmetic.
Behavioral counseling conducted in one office session followed by 4 cell-phone-based sessions. Counseling is based on models of behavioral self-management and cognitive decision making with the primary aim to increase antiretroviral adherence, engagement in HIV care, and reduction of sexual risk behaviors for HIV transmission.
Evidence over the past 30 years has revealed that 70-80% of individuals with schizophrenia exhibit marked neurocognitive deficits on measures of attention, learning and memory, problem-solving, language and sensory-motor skill. Particular significance has been attached to these deficits as their severity has been linked to impaired community function, social problem-solving and progress in psychosocial rehabilitation programs. Cognitive remediation (CR) is a type of behavioral intervention that addresses cognitive deficits in schizophrenia by restoring lost cognitive skills or providing strategies for bypassing deficits through task practice. Meta-analyses have revealed that cognitive remediation is a validated approach to improving cognitive function in schizophrenia, however a lack of precision regarding the active elements of the intervention have prevented its recommendation as a standard treatment for the illness. The present three-year proposal seeks to identify cognitive training mechanisms that are most effective at improving cognitive function in schizophrenia by comparing two different systematic programs of CR with different foci: drill-and-practice exercises vs. compensatory strategies. Both programs have strong preliminary empirical support. One-hundred and thirty-five clients diagnosed with schizophrenia or schizoaffective disorder will be randomly assigned to one of three groups: a neuroplasticity-based, drill-and-practice program of computer-assisted cognitive training exercises designed to restore lost cognitive capacity; a manualized strategy training method for bypassing deficits in cognition, or a computer games control condition. Study measures, organized according to an experimental therapeutics approach, with targets distinguished from outcomes, will assess generalization of any observed training effects.
This is a randomized (the study medication is assigned by chance), open-label (physicians and participants know the identity of the assigned treatment), single-center, single-dose, 3-treatment, 3-way crossover (the same medications provided to all participants but in different sequence) study of canagliflozin (CANA) and metformin extended release (MET XR) combined in one tablet, in comparison with tablets of individual components. Two Fixed Dose Combinations (FDCs) will be evaluated during the study (two types of tablets). The tablets will be of the same strength (50 mg CANA/500 mg MET XR) and will be compared with the equal doses of the individual drugs: canagliflozin (1 x 100 mg tablet) and metformin XR (2 x 500 mg tablets). Thus, there will be 3 treatment periods in the study: Treatment A: "Reference" treatment of individual components. Treatment B: CANA/MET XR FDC, formulation 1; and Treatment C: CANA/MET XR FDC, formulation 2. Approximately 42 healthy adult participants will be randomly assigned to 1 of 3 treatments groups, and then each group will receive all three treatments in different sequences (3-way crossover). The study will consist of 3 phases: a Screening Phase of approximately 3 weeks (Days -22 to -2), an Open-Label Treatment Phase consisting of 3 single-dose Treatment Periods of 5 days each (Days -1 through 4) separated by a washout of 10 to 14 days between Day 1 of each Treatment Period, and a Follow-up Phase occurring 7 to 10 days after the last study-related procedure on Day 4 of Treatment Period 3. The total duration of the study will be about 70 days for each participant.
PURPOSE:To obtain a composition for oral cavity application, having high safety and useful for the prevention of periodontosis, by using extract or crushed product of plants belonging to Thujopsis genus, Thuja genus or Juniperus genus of Cupressaceae family as a component. CONSTITUTION:Leaves or twigs of plants belonging to Thujopsis genus (e.g. Thujopsis dolabrata), Thuja genus (e.g. Thuja standasii) or Juniperus genus (e.g. Juniperus rigida and Juniperus chinensis) of Cupressaceae family is optionally dried and then crushed. The crushed product or its extract with ethanol, propylene glycol, water, etc., is used as a component of the objective composition for oral cavity application in an amount of 0.001-10wt.%, preferably 0.1-3wt.% in terms of dried residue based on the whole composition. When the component is used as an extract, it may be a solution as extracted, a concentrated extract obtained by distilling out the solvent or highly viscous material or powder produced by completely evaporating the solvent.
Targeting energy-demanding tissues in health and disease continues to be a challenging task in human nutrition and biomedicine. Impaired bioenergetics accompanies many different conditions, including cardiometabolic diseases, neurodegenerative disorders or high-intensity exercise, with various dietary interventions developed to restore cellular energy. Creatine is recognized as a beneficial and safe energy-boosting agent in both athletic and clinical environments. However, its effectiveness in specific conditions seems to be fairly restrained due to its limits in transportability and performance. Guanidinoacetic acid (GAA), a metabolic precursor of creatine, appears as a novel energy-enhancing supplement, with GAA being superior to creatine in facilitating creatine concentrations in the human brain and skeletal muscle. This perhaps happens due to GAA interaction with cellular transporters previously dismissed as untargetable carriers by other similar therapeutics. On the other hand, GAA loading remains under scrutiny due to its hyperhomocysteinemia-inducing potential, and possible neurotoxic effects. Co-administration of creatine and GAA has been recently proposed as a better strategy comparing to administration of each compound per se. Besides providing a competitive advantage for enhanced levels of tissue creatine, GAA-creatine mixture might also diminish side effects related to isolated GAA administration. However, no human studies so far evaluated the effects of this mixture. In the present study, the investigators compared the impact of 4-week co-administration of GAA and creatine vs. creatine administration alone on serum biomarkers, exercise performance and tissue bioenergetics in healthy young men.
BACKGROUND AND OBJECTIVE: Trigeminal Neuralgia (NT) is a common pathology in Neurosurgery. It can be classified as idiopathic or secondary to other pathologies, such as Multiple Sclerosis (MS). Several surgical treatments have been described, some of them being replaced by more modern techniques. Partial sensory rhizotomy (PSR), described by Dandy is a technique replaced by other techniques due to its permanent side effects. We present our experience with this technique in patients with recurrent NT.
METHODS AND MATERIALS: A retrospective review is carried out on five patients who underwent surgery at our center from 2018 to 2023 using the PSR technique.
RESULTS: All the patients intervened showed significant clinical improvement, except one patient who required reintervention due to uncontrolled pain. According to the Barrow Neurological Institute (BNI) scale, 80% (4/5) of patients showed improvement from grade V to grades I/II except for one of them. This patient suffered from MS. Additionally, one patient presented a corneal ulcer after surgery due to impairment of the corneal reflex.
CONCLUSION: In our experience, PSR is a valid treatment option in selected patients with recurrent TN. It has a low incidence of complications with an adequate surgical technique and anatomical knowledge of the region. To the best of our knowledge, we are one of the few centers in Spain to publish our results with PSR in the last ten years. We report good results in pain control withdrawing medication in 80% (4/5) of the operated patients.
FIELD: hygiene.SUBSTANCE: group of inventions relates to an oral composition and use thereof. Disclosed oral composition contains the following components (A) and (B): (A) is phytic acid or its alkali metal salt in amount of 0.04 wt. % to 1 wt. % in terms of phytic acid; (B) is monofluorophosphoric acid or its alkali metal salt in amount of 500 ppm up to 1,500 ppm in terms of fluorine atoms, wherein weight ratio of component (A) to component (B), ((A)/(B)) ranges from 0.1 to 1.4; pH of the composition ranges from 5.5 to 6.5. Composition does not contain or contains a compound which provides fluorine ions, (F), selected from a group consisting of sodium fluoride, potassium fluoride and ammonium fluoride, in amount of 100 ppm or less in terms of fluorine atoms; does not contain or contains a polyvalent metal cation in an amount less than 0.1-fold in terms of moles relative to component (A); does not contain or contains polyphosphoric acid or its salt in amount of 20 wt. % or less in terms of acid relative to component (A). Disclosed also is use of said composition for fluoride tooth absorption with inhibition of plaque formation on teeth, and use for tooth fluoride absorption with inhibition of plaque formation on teeth and glossy teeth.EFFECT: combination of components of composition enables to effectively inhibit formation of staining on dental surface, intensifying teeth whitening effect and effect, giving dental shine, and can also increase fluoride tooth absorption degree, providing effective inclusion of fluoride in enamel or dentin, and effectively weaken binding substance, which is result of application of phytic acid.13 cl, 5 tbl, 17 ex, 2 dwg
PURPOSE:To obtain a bathing agent, capable of effectively preventing and removing free radicals generated on the skin surface by ultraviolet rays and useful for removing and preventing the pruritus of the skin and preventing the skin from aging. CONSTITUTION:The objective bathing agent is obtained by using (A) sodium sulfate and/or sodium chloride and (B) a diester compound of phosphoric acid with L-ascorbic acid and tocopherol expressed by the formula (R1 and R2 are H or CH3) or its salt in combination. This bathing agent has the effects. Furthermore, although the concentration of the ingredient (B) blended in the bathing agent is suitably selected according to the kind of compound or dosage form, etc., of the bathing agent, it is usually about 0.001-5.0(wt./wt.)%, preferably about 0.01-0.5 (wt./wt.)%. When the sodium sulfate and sodium chloride are used together, the concentrations of the ingredients are preferably about 40-70(wt./wt.)% former and about 30-70(wt./wt.)% latter.
Aprepitant: 125mg PO on day1, 80mg PO on day2 and day3. Palonosetron (a 5-HT3 receptor antagonist): 0.25 mg IV push on day 1 only. Dexamethasone: 5mg IV push once daily from day 1 to day 3,and 3.75mg PO on days 4-5.
PURPOSE: To obtain the subject preventing agent, constituted of a crosslinked hyaluronic acid having mutually crosslinked carboxyl groups, insolubilized in water, retainable in tissuey lesions for a desired period and capable of sustaining effects and remarkably reducing the occurrence of postoperative adhesion. CONSTITUTION: This preventing agent is obtained by crosslinking carboxyl groups in a glucuronic acid residue constituting hyaluronic acid with a two terminal epoxy-containing compound-based crosslinking agent and represented by the formula. Furthermore, the crosslinking ratio between the carboxyl groups is preferably 0.5-5%. For example, the preventing agent is preferably prepared by dissolving (A) the hyaluronic acid, (B) the two terminal epoxy-containing compound which is the crosslinking agent (e.g. ethylene glycol diglycidyl ether) and (C) a neutral to a weak acidic solvent (e.g. a phosphate at pH4-7 in its aqueous solution such as monoammonium monophosphate) in pure water, then evaporating the water to dryness and providing a filmlike or a sheetlike form by heating.
An apparatus, system, and method optimize pathology workflow. The method performed at a workflow server includes receiving a plurality of digital slices associated with a pathology instance associated with first information characterizing the pathology instance. The method includes generating second information based on an analysis of the digital slice, the second information characterizing the digital slice. The method includes determining a plurality of tasks for use in completing the pathology example based on the first information and the second information. The method includes determining a task executor to be assigned to execute a selected one of the tasks. The method includes assigning an allocation to the task executor corresponding to the selected task.
Control participants will receive an identical sham splint to the active condition, but not adjusted to the recommended height for the given participant. Participants will be asked to wear the orthotic 24/7 for the duration of the study.
The invention comprises compounds of the formula <FORM:1099209/C2/1> in which A is hydrogen or C1- 6 alkyl, R1 is hydrogen or C1- 6 alkyl, R2 is chlorine, bromine fluorine or trifluoromethyl, R3 is <FORM:1099209/C2/2> and Y is oxygen or sulphur, and, when A is hydrogen, carboxylic acids salts thereof.  The compounds are prepared by the following reaction scheme: <FORM:1099209/C2/3> in which R1, R2 and R3 are as defined above, B is hydrogen or C1- 6 alkyl, lower alkyl is C1- 6 alkyl and X is chlorine, bromine or fluorine chosen so that when R2 is chlorine, X is chlorine or bromine, when R2 is bromine or trifluoromethyl, X is chlorine, bromine or fluorine and when R2 is fluorine, X is fluorine.  2 - Bromo - 5 - sulphamoyl (or n-butyl-sulphamoyl or n-hexyl-sulphamoyl)-4-trifluoromethylbenzoic acids is prepared by nitrating 2-bromo-4-trifluoromethylbenzoic acid to form 2-bromo-5-nitro - 4 - trifluoromethylbenzoic acid, reducing this to form 2-bromo-5-amino-4-trifluoromethylbenzoic acid, treating this with hydrochloric acid and sodium nitrate followed by a solution of sulphur dioxide in acetic acid containing cuprous chloride to form 2-bromo-5-chlorosulphonyl - 4- trifluoromethylbenzoic acid and reacting this with ammonium hydroxide, n-butylamine or n-hexylamine. 2,4 - Difluoro - 5 - methylsulphamoylbenzoic acid is prepared by reacting 2,4-difluorobenzoic acid with chlorosulphonic acid to form 2,4-difluoro-5 -chlorosulphonylbenzoic acid and reacting this compound with methylamine.  2 - Tetrahydrothiapyranylmethylamine is prepared by reacting 2-tetrahydropyrancarboxylic acid with ethyl chloroformate followed by ammonia to form 2-tetrahydrothiapyrancarboxylic acid amide and reducing this compound with lithium aluminium hydride.  3 - Tetrahydropyranylmethylamine is prepared by reacting 3-tetrahydropyrancarboxylic acid with methanol to form methyl 3-tetrahydropyrancarboxylate, reacting this compound with ammonia to form 3-tetrahydropyrancarboxylic acid amide and reducing this compound with lithium aluminium hydride. Pharmaceutical compositions having diuretic and antihypertensive activity, comprise a compound of the invention together with a carrier.
INTRODUCTION: The Burkholderia cepacia complex encompasses a group of gram-negative opportunistic pathogens that cause chronic lung infections in people with cystic fibrosis. Distinct from other respiratory pathogens, Burkholderia causes a unique clinical disease in a subset of patients known as 'cepacia syndrome', fulminant pneumonia accompanied by bacteraemia and sepsis with a mortality rate of up to 75%. Due to the bacteraemia associated with this disease, the mechanisms that allow Burkholderia to resist the bactericidal effects of serum complement-depending killing are vital. Antibodies usually promote serum killing; however, we have described 'cloaking antibodies', specific for lipopolysaccharides that paradoxically protect serum-sensitive bacteria from complement-mediated lysis. Cloaking antibodies that protect Pseudomonas aeruginosa have been found in 24%-41% of patients with chronic lung diseases. The presence of these antibodies is also associated with worse clinical outcomes. Here, we sought to determine the relevance of cloaking antibodies in patients with Burkholderia infection.
METHODS: Twelve Burkholderia spp. were isolated from nine pwCF and characterised for susceptibility to healthy control serum. Patient serum was analysed for the titre of the cloaking antibody. The ability of the patient serum to prevent healthy control serum (HCS) killing of its cognate isolates was determined.
RESULTS: We found that several of the Burkholderia strains were shared between patients. Ten of the 12 isolates were highly susceptible to HCS killing. Four of nine (44%) patients had cloaking antibodies that protected their cognate strain from serum killing. Depleting cloaking antibodies from patient serum restored HCS killing of Burkholderia isolates.
DISCUSSION: Cloaking antibodies are prevalent in patients with Burkholderia pulmonary infection and protect these strains from serum killing. Removal of cloaking antibodies via plasmapheresis, as previously described for individuals with life-threatening Pseudomonas infection, may be a useful new strategy for those with serious and life-threatening Burkholderia infection.
Smoking is the leading preventable cause of morbidity and mortality among women in the US. Quitting smoking may be especially problematic for women. As a form of exercise, yoga shares many of the same properties as traditional (Western) aerobic exercise which our previous research has shown to be an effective addition to smoking cessation. Yoga may also offer other benefits that may make it an especially effective complimentary treatment for women who are attempting to quit smoking.

In this study we will recruit two cohorts of 30 women smokers and provide cognitive-behavioral therapy for smoking cessation once weekly for 12 weeks. In addition, participants will be randomly assigned them to receive either; (1) Yoga or (2) a Wellness program (contact-control), twice weekly during the program. All participants will be assessed for changes in smoking behavior, psychosocial variables relevant to smoking cessation and other psychological constructs that may act as mechanisms of action (mediators) of yoga and smoking cessation. These variables include; weight concerns, perceived stress, mindfulness, self-esteem, quality of life and group cohesion. Interviews will be used to collect qualitative data at the end of each cohort. The proposed study is designed to provide information necessary to establish several research fundamentals necessary to support a full scale efficacy trial. These include: 1) establishing intervention feasibility and acceptability in the target population, 2) piloting recruitment and retention procedures and identifying barriers to participation, 3) obtaining qualitative feedback from participants to enhance treatment content and/or design, 4) establishing anticipated effect size estimates, and 5) identifying likely mechanisms of action that may be responsible for intervention efficacy.
The present invention relates to stable compositions comprising an isothiocyanate. It also relates to methods for stabilizing an isothiocyanate. According to the invention, sulforaphane is stabilized in the presence of fatty acids. Compositions prepared by mixing sulforaphane with certain amounts of a fatty acid or a mixture of fatty acids exhibit a stabilizing effect with respect to residual sulforaphane. It was found that such compositions can maintain sulforaphane, as expressed by % w/w, more effectively, i.e. stabilize it, compared to neat sulforaphane, under certain storage conditions. This facilitates the distribution of sulforaphane as a component to be used for industrial purposes, for example in the preparation of various products, dietary supplements, food additives, pharmaceuticals, nutraceuticals, cosmetics etc, because it makes long-term storage easier and efficient. No complex techniques are required for the stabilization, such as encapsulation or complexation, neither extremely low temperatures.
Helicobacter pylori infection is a well-established risk factor for peptic ulcer disease and gastric cancer. It's now a consensus of experts that H.pylori infection should be treated once it is recognized. Extended proton pump inhibitor (PPI)-based sequential therapy as one of the most commonly used first-line regimens provides a satisfactory eradication rate of 90.7% (95% CI, 87.4% - 94.0%). Nevertheless, its complexity of the "sequential" usage is sometimes confusing to the patients and may lead to treatment failure. The emerging new regimen - vonoprazan-based triple therapy, on the other hand, is another appealing choice with simplicity, short treatment duration, and low pill burden. However, there's still no evidence regarding the use of vonoprazan-based triple therapy with high-dose amoxicillin (1000mg twice daily) as the first-line regimen. This study aimed to compare the efficacy of the current standard first-line regimen, sequential therapy, with that of vonoprazan-based triple therapy with high-dose Amoxicillin.
Immunotherapy has achieved significant therapeutic effect in DNA mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC). MMR expression and MSS status are the important effective factors of immunotherapy. PD-1monocolnal antibody therapy has accessed excellent treatment effect in advanced dMMR/MSI-H CRC and neoadjuvant therapeutic effect in early colon cancer, more than fifty percent of dMMR/MSI-H CRC patients might get pathological complete response(pCR) after PD-1 monoclonal antibody treatment. The treatments had been proved to be safe and the toxicities were controllable. Rectal cancer(RC) is one of the most common malignant tumors in China. So far, radical resection with or without neoadjuvant chemotherapy of chemoradiotherapy are still standard comprehensive treatments recommended to distal RC by NCCN, ESMO and CSCO. For distant RC, radical resection and neoadjuvant chemotherapy or chemoradiotherapy might cause lots of treatment cost,damage to defecation and sexual function, acute toxicity, chronic dysfunction, even loss of anus and psychological disorder. So far, whether watch and wait could be performed in patients with dMMR/MSI-H distal RC accessed pCR after PD-1 monoclonal antibody therapy or not is still not clear. Thus, this study aims to evaluate the effect and safety of watch and wait in patients with dMMR/MSI-H distal RC accessed pCR after PD-1 monoclonal antibody therapy.